These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 32273395)

  • 1. Reslizumab as add-on therapy in patients with refractory asthma.
    Virchow JC; McDonald M; Garin M; Korn S
    BMJ Open Respir Res; 2020 Apr; 7(1):. PubMed ID: 32273395
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-utility analysis of reslizumab for patients with severe eosinophilic asthma inadequately controlled with high-dose inhaled corticosteroids and long-acting β
    Han S; Kim S; Kim H; Suh HS
    Curr Med Res Opin; 2019 Sep; 35(9):1597-1605. PubMed ID: 30964365
    [No Abstract]   [Full Text] [Related]  

  • 3. Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies.
    Albers FC; Price RG; Smith SG; Yancey SW
    J Allergy Clin Immunol; 2017 Nov; 140(5):1464-1466.e4. PubMed ID: 28687231
    [No Abstract]   [Full Text] [Related]  

  • 4. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma.
    Chipps BE; Newbold P; Hirsch I; Trudo F; Goldman M
    Ann Allergy Asthma Immunol; 2018 May; 120(5):504-511.e4. PubMed ID: 29409951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reslizumab in Eosinophilic Asthma: A Review.
    Deeks ED; Brusselle G
    Drugs; 2017 May; 77(7):777-784. PubMed ID: 28421429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Outcomes and Health-Care Resource Use Associated With Reslizumab Treatment in Adults With Severe Eosinophilic Asthma in Real-World Practice.
    Wechsler ME; Peters SP; Hill TD; Ariely R; DePietro MR; Driessen MT; Terasawa EL; Thomason DR; Panettieri RA
    Chest; 2021 May; 159(5):1734-1746. PubMed ID: 33333058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.
    Weinstein SF; Katial RK; Bardin P; Korn S; McDonald M; Garin M; Bateman ED; Hoyte FCL; Germinaro M
    J Allergy Clin Immunol Pract; 2019 Feb; 7(2):589-596.e3. PubMed ID: 30193936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study.
    Bjermer L; Lemiere C; Maspero J; Weiss S; Zangrilli J; Germinaro M
    Chest; 2016 Oct; 150(4):789-798. PubMed ID: 27056586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mepolizumab use: Post-approval academic practice experience.
    Benjamin MR; Bochner BS; Peters AT
    Ann Allergy Asthma Immunol; 2018 Jul; 121(1):126-128. PubMed ID: 29653234
    [No Abstract]   [Full Text] [Related]  

  • 10. Adherence to inhaled corticosteroids and clinical outcomes following a year of benralizumab therapy for severe eosinophilic asthma.
    d'Ancona G; Kavanagh JE; Dhariwal J; Hearn AP; Roxas C; Fernandes M; Green L; Thomson L; Nanzer AM; Jackson DJ; Kent BD
    Allergy; 2021 Jul; 76(7):2238-2241. PubMed ID: 33432682
    [No Abstract]   [Full Text] [Related]  

  • 11. Mepolizumab in the treatment of severe eosinophilic asthma: Results from a physician in the field.
    Strauss RA; Jawhari N
    Ann Allergy Asthma Immunol; 2018 Jul; 121(1):121-123. PubMed ID: 29684570
    [No Abstract]   [Full Text] [Related]  

  • 12. Mepolizumab (Nucala) for severe eosinophilic asthma.
    Med Lett Drugs Ther; 2016 Jan; 58(1486):11-2. PubMed ID: 26761344
    [No Abstract]   [Full Text] [Related]  

  • 13. Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts.
    Corren J; Weinstein S; Janka L; Zangrilli J; Garin M
    Chest; 2016 Oct; 150(4):799-810. PubMed ID: 27018175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reslizumab in the treatment of severe eosinophilic asthma: an update.
    Walsh GM
    Immunotherapy; 2018 Jun; 10(8):695-698. PubMed ID: 29554826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of reslizumab in patients with moderate to severe eosinophilic asthma.
    Lim HF; Nair P
    Expert Rev Respir Med; 2015 Apr; 9(2):135-42. PubMed ID: 25578680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biologic Therapy in a Patient with Asthma and Nasal Polyps.
    Caminati M; Senna G
    J Allergy Clin Immunol Pract; 2019; 7(5):1700-1701. PubMed ID: 31076065
    [No Abstract]   [Full Text] [Related]  

  • 17. Does omalizumab make a difference to the real-life treatment of asthma exacerbations?: Results from a large cohort of patients with severe uncontrolled asthma.
    Grimaldi-Bensouda L; Zureik M; Aubier M; Humbert M; Levy J; Benichou J; Molimard M; Abenhaim L;
    Chest; 2013 Feb; 143(2):398-405. PubMed ID: 23505637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe uncontrolled eosinophilic asthma, which responded to benralizumab after failure to respond to mepolizumab.
    Kurosawa M; Sutoh E
    Ann Allergy Asthma Immunol; 2019 Apr; 122(4):431-433. PubMed ID: 30578859
    [No Abstract]   [Full Text] [Related]  

  • 19. Predicting Responders to Reslizumab after 16 Weeks of Treatment Using an Algorithm Derived from Clinical Studies of Patients with Severe Eosinophilic Asthma.
    Bateman ED; Djukanović R; Castro M; Canvin J; Germinaro M; Noble R; Garin M; Buhl R
    Am J Respir Crit Care Med; 2019 Feb; 199(4):489-495. PubMed ID: 30346831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mometasone/Formoterol (dulera) for asthma.
    Med Lett Drugs Ther; 2010 Oct; 52(1349):83-4. PubMed ID: 21045758
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.